Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy

Cancer Immunology, Immunotherapy

Volumn 51, Issue 10, 2002, Pages 521-531

  Dredge, Keith ^a   Marriott, Blake J ^a   Todryk, Stephen M ^b   Dalgleish, Angus G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cytokine; Immune adjuvant; Th 1 immunity; Tumour immunotherapy

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CARCINOEMBRYONIC ANTIGEN; CPG OLIGONUCLEOTIDE; CYCLOPHOSPHAMIDE; DNA VACCINE; DOXORUBICIN; FREUND ADJUVANT; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT KILLED BRUCELLA ABORTUS ADJUVANT; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 2; ISA 51; PEPTIDE DERIVATIVE; PROLACTIN; QS 21; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 12; SRL 172; T LYMPHOCYTE RECEPTOR; THALIDOMIDE; THYMIDINE KINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VIRUS ADJUVANT;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOGENICITY; KIDNEY CARCINOMA; MACROPHAGE; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; MODELS, IMMUNOLOGICAL; NEOPLASMS; TH1 CELLS;

EID: 0036034742     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0309-z     Document Type: Review

References (79)

1. Alexandroff AB, Jackson AM, O'Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689
2. + T cells requires tumor responsiveness to IFN-γ. J Immunol 166:2276
3. + cytotoxic T lymphocyte attack. Cancer Immunol Immunother 49:193
4. Bohle B, Jahn-Schmid B, Maurer D, Kraft D, Ebner C (1999) Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol 29:2344
5. Casares N, Lasarte JJ, de Cerio AL, Sarobe P, Ruiz M, Melero I, Prieto J, Borras-Cuesta F (2001) Immunization with a tumour-associated CTL epitope plus a tumour-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol 31:1780
6. Chang A, Metz DH (1976) Further investigations on the mode of entry of Vaccinia virus into cells. J Gen Virol 32:275
7. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623
8. Dalgleish AG (2000) Cancer vaccines. Br J Cancer 82:1619
9. Davies ID (2000) An overview of cancer immunotherapy. Immunol Cell Biol 78:179
10. Dreicer R, See WA, Klein EA (2001) Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs 19:261
11. Dredge K, Marriott JB, Todryk S, Muller GW, Chen R, Stirling DI, Dalgleish AG (2002) Protective anti-tumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168:4914
12. Duda RB, Yang H, Dooley DD, Abu-Jawdeh G (1995) Recombinant BCG therapy suppresses melanoma tumour growth. Ann Surg Oncol 6:542
13. Durrant LG, Parsons T, Moss R, Spendlove I, Carter G, Carr F (2001) Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses. Int J Cancer 92:414
14. + T cell-dependent tumor eradication in vivo. J Immunol 165:5495
15. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumour immunotherapy. Proc Natl Acad Sci USA 98:8809
16. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee SK, Bhattacharya-Chatterjee M (1999) Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 17:2889
17. Frassanito MA, Cusmai A, Dammacco F (2001) Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol 125:190
18. Fujimoto T, O'Donnell MA, Szilvasi A, Yang H, Duda RB (1996) Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol Immunother 42:280
19. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61:8513
20. Gherardi MM, Ramirez JC, Esteban M (2001) Towards a new generation of vaccines: The cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histol Histopathol 16:655
21. Gilboa E (1999) How tumours escape immune destruction and what we can do about it. Cancer Immunol Immunother 48:382
22. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Moller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G (2001) Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441
23. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 15:1950
24. Hafner M, Zawatzky R, Hirtreiter C, Buurman WA, Echtenacher B, Hehlgans T, Mannel DN (2001) Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res 61:5523
25. + subset. J Exp Med 187:1885
26. Heath WR, Carbone FR (2001) Cross-presentation in viral immunity and self-tolerance. Nature Immunol 1:126
27. Ho RL, Maccubbin DL, Ujhazy P, Zaleskis G, Eppolito C, Mihich E, Ehrke MJ (1993) Immunological responses critical to the therapeutic effects of adriamycin plus interleukin-2 in C57BL/6 mice bearing syngeneic EL4 lymphoma. Oncol Res 5:363
28. Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG (1998) Immunotherapy of advanced prostate cancer: A phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 82:568
29. Huang LY, Reis e Sousa C, Itoh Y, Inman J, Scott DE (2001) IL-12 induction by a Th1-inducing adjuvant in vivo: Dendritic cell subsets and regulation by IL-10. J Immunol 167:1423
30. + T cells in the antitumor immune response. J Exp Med 188:2357
31. Hunger RE, Brand CU, Streit M, Eriksen JA, Gjertsen MK, Saeterdal I, Braathen LR, Gaudernack G (2001) Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp Dermatol 10:161
32. Jager E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jaer D, Ilsemann C, Hagedorn M, Oesch F, Knuth A (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54
33. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243
34. Kankuri M, Pelliniemi TT, Pyrhonen S, Nikkanen V, Helenius H, Salminen E (2001) Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: A phase II study. Cancer 92:761
35. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW (2001) Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 61:206
36. + T cell-mediated eradication of established tumours by peritumoural injection of CPG-containing oligodeoxynucleotides. J Immunol 167:5247
37. Kim EM, Sivanandham M, Stravropoulos CI, Bartolucci AA, Wallack MK (2001) Overview analysis of adjuvant therapies for melanoma - A special reference to results from Vaccinia melanoma oncolysate adjuvant therapy trials. Surg Oncol 10:53
38. Kim JJ, Yang JS, Dang K, Manson KH, Weiner DB (2001) Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin Cancer Res 7:882S
39. Kim JJ, Yang JS, Manson KH, Weiner DB (2001) Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine 19: 2496
40. Kusumoto M, Umeda S, Ikubo A, Aoki Y, Tawfik O, Oben R, Williamson S, Jewell W, Suzuki T (2001) Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother 50:373
41. Labidi AH, Estes RC, David HL, Bollon AP. (2001) Mycobacterium recombinant vaccines. Tunis Med 79:65
42. Larsson M, Fonteneau JF, Somersan S, Sanders C, Bickham K, Thomas EK, Mahnke K, Bhardwaj N (2001) Efficiency of cross presentation of Vaccinia virus-derived antigens by human dendritic cells. Eur J Immunol 12:3432
43. Lesimple T, Moisan A, Guille F, Leberre C, Audran R, Drenou B, Toujas L (2000) Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte-macrophage colony-stimulating factor. J Immunother 23(6):675
44. Lotze MT (1995) Biological therapy with interleukin-2: Preclinical studies. In: DeVita VT, Hellman S, Rosenberg SA (eds) Biologic Therapy of Cancer, vol 195. Lippincott, Philadelphia, p 207
45. Marriott JB, Muller G, Dalgleish AG (1999) Thalidomide as an emerging immunotherapeutic agent. Immunol Today 20:538
46. Matar P, Rozados VR, Gervasoni SI, Scharovsky GO (2002) Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 50:588
47. Matikainen S, Paananen A, Miettinen M, Kurimoto M, Timonen T, Julkunen I, Sareneva T (2001) IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: Differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur J Immunol 31:2236
48. Maumber B, Biswas R, Chattopadhyay U (2002) Prolactin regulates antitumor immune response through induction of tumoricidal macrophages and release of IL-12. Int J Cancer 97:493
49. Melcher A Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG (1998) Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 4:581
50. Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, Romero P (2002) CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 168:1212
51. Mihich E, Ehrke MJ (2000) Anticancer drugs plus cytokines: Immunomodulation based therapies of mouse tumors. Int J Immunopharmacol 22:1077
52. Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 46: 5276
53. Murray PJ, Aldovini A, Young RA (1996) Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc Natl Acad Sci USA 93:934
54. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohta A (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190:617
55. Nishisaka N, Jones RF, Morse P, Kuratsukuri K, Romanowski R, Wang CY, Haas GP (2001) Inhibition of lung metastases of murine renal cell carcinoma by the combination of radiation and interferon-alpha-producing tumour cell vaccine. Cytokines Cell Mol Ther 6:199
56. Ostrand-Rosenberg S, Pulaski BA, Clements VK, Qi L, Pipeling MR, Hanyok LA (1999) Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol Rev 170:101
57. Overwijk WW (2000) Enhancing therapeutic anticancer vaccines. Cancer J Sci Am 6:576
58. Pawelec G (1999) Tumour escape from the immune response: The last hurdle for successful immunotherapy of cancer? Cancer Immunol Immunother 48:343
59. Platten M, Wick W, Weller M (2001) Malignant glioma biology: Role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52:401
60. + T cell clones. Cancer Immunol Immunother 50:615
61. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90:4645
62. Re F, Stominger JL (2001) Toll-like receptor-2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 276:37692
63. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 3:269
64. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Sznol M, Schwarz SL, Spiess PJ, Wunderlich JR, Seipp CA, Einhorn JH, Rogers-Freezer L, White DE (1999) Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163:1690
65. Sabel MS, Hill H, Jong YS, Mathiowitz E, Bankert RB, Egilmez N (2001) Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery 130:470
66. Scheerlinck JY (2001) Genetic adjuvants for DNA vaccines. Vaccine 19:2647
67. Schweighoffer T (1996) Tumor cells expressing a recall antigen are powerful cancer vaccines. Eur J Immunol 26:2559
68. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107
69. Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG (2001) Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin Cancer Res 7:3012
70. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL (1998) Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. Immunity 8:657
71. Takasu H (2001) Interferon-alpha: An effective adjuvant for peptide-based cytotoxic T-cell vaccines. Kurume Med J 48:171
72. Toda M, Martuza RL, Rabkin SD (2001) Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther 8:332
73. Todryk SM, Melcher AA, Dalgleish AG, Vile RG (2000) Heat shock proteins refine the danger theory. Immunology 99:334
74. Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG (1998) Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 163:1398
75. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54:6228
76. Vile RG Castleden S, Marshall J, Camplejohn R, Upton C, Chong H (1997) Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 71:267
77. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM (2001) Regulation of toll-like receptors in human monocytes and dendritic cells. J Immunol 166:248
78. Wu KS, Ueda S, Sakaue Y, Ohashi Y, Ikuta K, Sugano T, Kato S (1981) Prevention of syngeneic tumour growth in Vaccinia virus-modified tumour cells. Biken J 24:153
79. Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U (2000) Murine IL-2 secreting recombinant bacillus Calmette-Guérin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol 164: 526